Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
Jana HurnakovaHana HulejovaJakub ZavadaMartin KomarcPetra HanovaMartin KleinHerman MannOlga SleglovaMarta OlejarovaSarka ForejtovaOlga RuzickovaJiri VencovskyKarel PavelkaLadislav SenoltPublished in: PloS one (2016)
The present study demonstrates the potential of calprotectin to distinguish RA patients in both clinical and ultrasound-defined remission from patients in clinical remission but with residual subclinical disease activity.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- end stage renal disease
- juvenile idiopathic arthritis
- ejection fraction
- magnetic resonance imaging
- chronic kidney disease
- peritoneal dialysis
- patient reported outcomes
- patient reported
- idiopathic pulmonary fibrosis